At ESMO 2024, Lantheus will present additional clinical data from the Phase 3 SPLASH trial on 177Lu-PNT2002, a PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer ...

If the $12.50-per-share all-cash deal is completed, it will give Lilly a stake in a PSMA-targeted radioligand therapy – PNT2002 – which is in the phase 3 SPLASH trial in patients with ...

Just a few months ago, Lilly snapped up POINT Biopharma for around $1.4 billion, adding a PSMA-targeted radioligand therapy called PNT2002, which is in the phase 3 SPLASH trial in patients with ...

After hours: 12 February at 6:23:24 pm GMT-5 ...